XOMA Ltd: All Recent News

• All recent news
• Earnings news

XOMA Receives NASDAQ Determination Letter 11/19/2009

BERKELEY, Calif., Nov. 19, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that it received a letter from the staff of The NASDAQ Stock Market LLC on November 13, 2009 indicating that the NASDAQ staff has concluded that XOMA's previously-announced common share financing completed on September 30, 2009 did not comply with NASDAQ's Listing Rule 5635(d)(2). Listing Rule 5635(d)(2) requires that a company obtain shareholder approval for the issuance of common shares or securities exercisable for common shares equal... GlobeNewswire

XOMA Appoints Jim Neal Vice President of Business Development 11/17/2009

BERKELEY, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that James R. Neal has joined the company as Vice President, Business Development. Mr. Neal will oversee XOMA's business development strategy and lead the team to execute key licensing initiatives to build and support XOMA's proprietary therapeutic pipeline and biodefense programs, to market the company's antibody technologies and to assess commercial opportunities and develop product candidates commercially. GlobeNewswire

XOMA 052 Selected as a Top Ten Project to Watch 11/12/2009

BERKELEY, Calif., Nov. 12, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced its anti-inflammatory antibody to interleukin-1 beta (IL-1 beta), XOMA 052, has been selected as a Top Ten Cardiovascular/metabolic Project to Watch for partnering opportunities. The selection was made by Windhover and Elsevier Business Intelligence, the leading provider of business intelligence and analysis in the pharmaceutical, biotechnology and medical device industries. GlobeNewswire

XOMA Announces Presentation at Lazard Healthcare Conference on... 11/11/2009

BERKELEY, Calif., Nov. 11, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Fred Kurland, Vice President and Chief Financial Officer of XOMA, is scheduled to present at the 6th annual Lazard Healthcare Conference on Wednesday, November 18, at 1:45 pm. Eastern time in New York City. GlobeNewswire

XOMA Reports 2009 Third Quarter Financial Results 11/9/2009

BERKELEY, Calif., Nov. 9, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the third quarter and nine months ended September 30, 2009 and provided a general business update. XOMA has made significant progress in 2009 toward its objective of becoming a company focused on proprietary product development and has done so while generating revenues from its technology licensing collaborations, royalties and biodefense businesses in difficult circumstances that included the removal of... GlobeNewswire

XOMA Expands Development Strategy for XOMA 052 to Include... 11/6/2009

BERKELEY, Calif., Nov. 6, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the expansion of its development strategy for its XOMA 052 antibody to interleukin-1 beta (IL-1 beta) to include effects on cholesterol lowering, reducing plaque deposits and damage to heart muscle and resulting long-term effects that can lead to heart attack, stroke and congestive heart failure. The strategy is supported by results from XOMA 052 Phase 1 trials demonstrating improvement in biomarkers associated with cardiovascular risk,... GlobeNewswire

XOMA Granted First European Patent Covering XOMA 052 11/4/2009

BERKELEY, Calif., Nov. 4, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the grant of its first European Patent related to the XOMA 052 program. Granted by the European Patent Office, the patent covers XOMA's interleukin-1 beta (IL-1 beta) antibody XOMA 052, as well as nucleic acids, expression vectors and production cell lines for the manufacture of XOMA 052. The patent provides exclusivity in Europe into 2026. GlobeNewswire

XOMA to Announce Third Quarter 2009 Financial Results and Host... 11/3/2009

BERKELEY, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that the company will host a conference call and webcast on Monday, November 9 at 9:00 a.m. Eastern time to discuss third quarter 2009 financial results and provide a general business update. GlobeNewswire

XOMA Signs Antibody Discovery Collaboration With Kaketsuken 11/3/2009

BERKELEY, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) and Kaketsuken have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new XOMA antibody phage display library, and a suite of integrated information and data management systems. Subject to certain technical verification required under the collaboration agreement, Kaketsuken has agreed to pay XOMA a fee of $8 million and XOMA will be entitled to milestone payments and royalties on product sales. Founded in 1926 in Japan as the... GlobeNewswire

More News

Market Report

News by Symbol

Today's Investing Articles

Breaking News

News by Topic

News by Industry

MSNBC News

MSN Money

Search MSN Money

Message Boards

Site Status